Treatment at last follow-up
| Syncope | AVT+ | AVT– | Non-syncope | AVT+ | AVT– | p-value (syncope versus non-syncope) | |
| Subjects n | 42 | 14 | 28 | 67 | 14 | 53 | |
| CCB for vasoresponsiveness | 10 (24) | 10# | 0 | 6 (6) | 6# | 0 | 0.03 |
| CCB monotherapy | 3 (6) | 3¶ | 0 | 3 (3) | 3¶ | 0 | 0.67 |
| Single PAH therapy | 6 (14) | 4 | 2 | 18 (27) | 5 | 13 | 0.12 |
| Dual PAH therapy | 13 (31) | 3 | 10 | 11 (16) | 1 | 10 | 0.07 |
| Triple PAH therapy | 18 (43) | 3¶ | 15 | 23(34) | 3 | 21 | 0.37 |
| No medication | 2 (4) | 1 | 1 | 12 (18) | 2 | 10 | 0.046 |
| IV/SQ prostanoid | 20 (48) | 1 (7) | 19+ (68) | 15 (22) | 1 (7) | 14 (26) | 0.006 |
Data are expressed as n or n (%). Bold p-values represent statistically significant differences between patients with and without syncope. AVT: acute vasodilator testing; CCB: calcium channel blocker; PAH: pulmonary arterial hypertension; IV: intravenous; SQ: subcutaneous. #: p for AVT+ versus AVT– <0.00001; ¶: p for AVT+ versus AVT– <0.05 (for syncope CCB only, p=0.03; for syncope triple PAH therapy, p=0.047; for non-syncope CCB only, p=0.007); +: p for AVT+ versus AVT– =0.0002.